Co-published by Adv. Yehuda Neubauer, Partner, Ehrlich, Neubauer & Melzer of Ehrlich Group and Intellectual Asset Magazine(IAM) According to the Israel Patent Office’s (ILPO) annual reports, there has been a steady increase in the last two years in the number of design applications made by international corporations. More specifically, there was a considerable rise in …
By: Dr. Hadassa Waterman, Head of the Biotech Department, Ehrlich & Fenster of Ehrlich Group Drug repurposing has been around for centuries. However, a recent report shows that in the last few years, Drug Repurposing, Repositioning and Rescue (DRPx) products are about 30% of the annual revenues of the entire pharma industry. This is a very interesting …
By: Patent Attorneys Dr. Hadassa Waterman, Head of the Biotech Department and Dr. David Mencher, of Ehrlich & Fenster of Ehrlich Group Current USPTO guidelines for antibody-based inventions (see “Guidelines”1) have overturned the long-standing “antibody exception” to the 112 Written Description requirement for correlation between structure and function defining the boundaries of a group (genus) …
Co-authors: Mrs. Patricia Toma and Adv. Yissachar Bertisch, Foreign Filing Department, Ehrlich & Fenster of Ehrlich Group. Patent Marking is accomplished by labelling a manufactured product and/or its packaging, protected by patents(s), with patent identification number(s). In the U.S., 35 U.S.C 287 permits a patent holder to seek injunction as well as compensation against infringement, …
By Adv. Yehuda Neubauer, Partner, Ehrlich, Neubauer & Melzer of Ehrlich Group. The European Council recently approved the new copyright directive that updates the current copyright law within the European union (Directive of The European Parliament and of the Council on Copyright and Related Rights in the Digital Single Market and Amending Directives 96/9/EC and …
By Dr. Hadassa Waterman, Head of Biotech Department, Ehrlich & Fenster of Ehrlich Group. The President of the EPO has referred questions to the Enlarged Board of Appeal on the controversial issue of patent-eligibility of plants obtained by essentially biological processes. The referral is now pending as case G3/19. This means that as long as the issue …
The Ehrlich Group has filed approximately 30 patent applications for coronavirus-related technologies, on behalf of dozens of Israeli entrepreneurs.
By Adv. & Patent Attorney Roy Melzer, Head of Software, Information Sys. Department The European patent office (EPO) recently published its revised guidelines for examination. The new guidelines include a new section that specifically addresses Artificial intelligence (AI) and machine learning inventions, which are defined as computational models and algorithms for classification, clustering, regression and …
By: Dr. Jacob Blumenthal and Maier Fenster, Ehrlich & Fenster of Ehrlich Group. A few days ago I received an e-mail from one of our clients saying ” Dear Jacob, we are about to present our clinical study results in two weeks from today. Will that affect our intellectual property protection?”. Of course it will. Many …
By Adv. Yehuda Neubauer, Partner, Ehrlich, Neubauer & Melzer of Ehrlich Group. In Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc. dated January 22, 2019, The United States Supreme Court unanimously held that the sale of an invention to a party that is obligated to keep the invention confidential may be considered “on sale” for the …